[{"id":"ef9f9bd0-273f-42be-ab92-31c003721bbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01861106","created_at":"2021-01-18T08:19:16.098Z","updated_at":"2025-02-25T12:26:02.331Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","source_id_and_acronym":"NCT01861106","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GATA2","pipe":" | ","alterations":" GATA2 mutation","tags":["GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GATA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 07/24/2013","start_date":" 07/24/2013","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-24"},{"id":"1858e4d9-b3bc-4f84-941b-cd90075ac7b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708054","created_at":"2021-01-19T20:51:54.886Z","updated_at":"2025-02-25T14:08:06.998Z","phase":"Phase 2","brief_title":"Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS","source_id_and_acronym":"NCT04708054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-18"},{"id":"4b1b80e8-bcd8-4a78-8ae1-fe238c0362b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126916","created_at":"2021-01-18T15:24:54.957Z","updated_at":"2025-02-25T15:10:35.328Z","phase":"Phase 3","brief_title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","source_id_and_acronym":"NCT03126916","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 724","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"f18181fc-ba3a-410b-9369-091830924976","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457556","created_at":"2022-09-07T16:55:34.255Z","updated_at":"2025-02-25T15:12:56.234Z","phase":"Phase 3","brief_title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05457556","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 435","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"23df8c55-37d1-4d81-9a8c-51e5c6811bf0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03983850","created_at":"2021-01-18T19:35:37.156Z","updated_at":"2025-02-25T15:26:05.857Z","phase":"Phase 1/2","brief_title":"Optimizing PTCy Dose and Timing","source_id_and_acronym":"NCT03983850","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • PTEN • IGH • FBXW7","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS • PTEN • IGH • FBXW7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 07/09/2019","start_date":" 07/09/2019","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-11"},{"id":"ac72e48c-1524-449b-acbb-64797b142680","acronym":"","url":"https://clinicaltrials.gov/study/NCT04965597","created_at":"2021-07-16T13:53:25.569Z","updated_at":"2025-02-25T16:32:32.043Z","phase":"Phase 2","brief_title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","source_id_and_acronym":"NCT04965597","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C","pipe":" | ","alterations":" LDH elevation","tags":["HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • busulfan • Grafapex (treosulfan) • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-07"},{"id":"91e34a00-0291-46e3-8305-1607660e8c78","acronym":"","url":"https://clinicaltrials.gov/study/NCT04994808","created_at":"2021-08-06T12:53:07.543Z","updated_at":"2025-02-25T16:45:30.587Z","phase":"Phase 2","brief_title":"Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia","source_id_and_acronym":"NCT04994808","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • fludarabine IV • busulfan • Grafapex (treosulfan)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/11/2023","start_date":" 08/11/2023","primary_txt":" Primary completion: 10/03/2026","primary_completion_date":" 10/03/2026","study_txt":" Completion: 04/03/2027","study_completion_date":" 04/03/2027","last_update_posted":"2025-02-05"},{"id":"cb1a79b5-e061-4b3c-834a-601d77043b7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02512497","created_at":"2021-01-18T12:08:16.611Z","updated_at":"2025-02-25T14:35:44.470Z","phase":"Phase 1","brief_title":"Romidepsin Maintenance After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT02512497","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • fludarabine IV • busulfan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/08/2017","start_date":" 12/08/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-10-29"},{"id":"fd746a04-cf2a-4fe6-8ac1-71be01980b12","acronym":"","url":"https://clinicaltrials.gov/study/NCT03016806","created_at":"2021-01-18T14:50:46.648Z","updated_at":"2025-02-25T14:14:55.178Z","phase":"Phase 1","brief_title":"Umbilical Cord Blood Transplantation From Unrelated Donors","source_id_and_acronym":"NCT03016806","lead_sponsor":"University of Rochester","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-08-19"},{"id":"ea8aa5eb-747e-43c1-9888-86c7239699c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00547196","created_at":"2021-01-18T01:59:32.370Z","updated_at":"2024-07-02T16:34:25.798Z","phase":"","brief_title":"AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies \u0026 Disorders","source_id_and_acronym":"NCT00547196","lead_sponsor":"City of Hope Medical Center","biomarkers":" KMT2A • HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/16/2005","start_date":" 08/16/2005","primary_txt":" Primary completion: 11/11/2009","primary_completion_date":" 11/11/2009","study_txt":" Completion: 05/28/2024","study_completion_date":" 05/28/2024","last_update_posted":"2024-06-14"},{"id":"fe8da34f-8155-4e53-a434-b93819c389c5","acronym":"OPTIMIZE","url":"https://clinicaltrials.gov/study/NCT06001385","created_at":"2023-08-21T14:08:42.896Z","updated_at":"2024-07-02T16:34:27.204Z","phase":"Phase 2","brief_title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","source_id_and_acronym":"NCT06001385 - OPTIMIZE","lead_sponsor":"Center for International Blood and Marrow Transplant Research","biomarkers":" HLA-DRB1 • HLA-B • HLA-DPB1 • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-DPB1 • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 12/08/2023","start_date":" 12/08/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-06-11"},{"id":"75104445-162f-444f-84ea-8038034ab832","acronym":"","url":"https://clinicaltrials.gov/study/NCT02727803","created_at":"2021-01-18T13:21:10.406Z","updated_at":"2024-07-02T16:34:36.895Z","phase":"Phase 2","brief_title":"Personalized NK Cell Therapy in CBT","source_id_and_acronym":"NCT02727803","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • BCL2","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • busulfan • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/19/2016","start_date":" 05/19/2016","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-06-10"},{"id":"9209a8c3-cb61-49cb-9b57-ded111720987","acronym":"","url":"https://clinicaltrials.gov/study/NCT01701986","created_at":"2021-01-18T07:24:10.982Z","updated_at":"2024-07-02T16:34:37.196Z","phase":"Phase 1/2","brief_title":"Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma","source_id_and_acronym":"NCT01701986","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • clofarabine • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • busulfan • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 10/25/2012","start_date":" 10/25/2012","primary_txt":" Primary completion: 06/05/2024","primary_completion_date":" 06/05/2024","study_txt":" Completion: 06/05/2024","study_completion_date":" 06/05/2024","last_update_posted":"2024-06-07"},{"id":"a652e199-25c7-474e-ae48-fce734badcf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03579875","created_at":"2021-01-18T17:36:44.603Z","updated_at":"2024-07-02T16:34:37.677Z","phase":"Phase 2","brief_title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","source_id_and_acronym":"NCT03579875","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/13/2018","start_date":" 11/13/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/05/2029","study_completion_date":" 01/05/2029","last_update_posted":"2024-06-06"},{"id":"86dc7e81-ec59-452b-a3ee-1c37d19391d6","acronym":"NCI-2019-03188","url":"https://clinicaltrials.gov/study/NCT03970096","created_at":"2021-01-18T19:31:38.073Z","updated_at":"2024-07-02T16:35:00.086Z","phase":"Phase 2","brief_title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT03970096 - NCI-2019-03188","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • thiotepa • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/19/2019","start_date":" 11/19/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-05-30"},{"id":"34e695f6-dbe3-425d-b9ce-de960e381284","acronym":"","url":"https://clinicaltrials.gov/study/NCT04644016","created_at":"2021-01-19T20:39:14.570Z","updated_at":"2024-07-02T16:35:01.196Z","phase":"Phase 2","brief_title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","source_id_and_acronym":"NCT04644016","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 11/20/2020","start_date":" 11/20/2020","primary_txt":" Primary completion: 12/20/2025","primary_completion_date":" 12/20/2025","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2024-05-24"},{"id":"cd5cf9d3-98a9-4678-a914-8b4e2b5f403f","acronym":"ACCESS","url":"https://clinicaltrials.gov/study/NCT04904588","created_at":"2021-05-27T12:53:04.457Z","updated_at":"2024-07-02T16:35:01.309Z","phase":"Phase 2","brief_title":"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide","source_id_and_acronym":"NCT04904588 - ACCESS","lead_sponsor":"Center for International Blood and Marrow Transplant Research","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-DPB1 • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-DPB1 • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-05-23"},{"id":"d7ed8a2f-8937-4cbd-aa4d-ea29935f9c24","acronym":"","url":"https://clinicaltrials.gov/study/NCT04195633","created_at":"2021-01-18T20:26:55.926Z","updated_at":"2024-07-02T16:35:01.612Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","source_id_and_acronym":"NCT04195633","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-23"},{"id":"1d61c822-8b23-4a8f-b429-8c238d66ec51","acronym":"HR-NBL2","url":"https://clinicaltrials.gov/study/NCT04221035","created_at":"2021-01-18T20:32:43.345Z","updated_at":"2024-07-02T16:35:03.584Z","phase":"Phase 3","brief_title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","source_id_and_acronym":"NCT04221035 - HR-NBL2","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" MYCN • MYCL","pipe":" | ","alterations":" MYCN amplification • MYCL amplification","tags":["MYCN • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dacarbazine • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • cyclophosphamide intravenous • vindesine"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 11/05/2019","start_date":" 11/05/2019","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2032","study_completion_date":" 11/01/2032","last_update_posted":"2024-05-15"},{"id":"15ee9486-9dcc-4c8c-8158-5823809b90ac","acronym":"FluBuBe","url":"https://clinicaltrials.gov/study/NCT04942730","created_at":"2021-06-28T17:52:48.047Z","updated_at":"2024-07-02T16:35:05.320Z","phase":"Phase 2","brief_title":"Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)","source_id_and_acronym":"NCT04942730 - FluBuBe","lead_sponsor":"St. Petersburg State Pavlov Medical University","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 01/21/2021","start_date":" 01/21/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2024-05-07"},{"id":"da79fe71-e09f-48b0-9ffb-5c6b712e843b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05569512","created_at":"2022-10-06T13:55:46.803Z","updated_at":"2024-07-02T16:35:06.360Z","phase":"Phase 1/2","brief_title":"Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML","source_id_and_acronym":"NCT05569512","lead_sponsor":"Malika Kapadia","biomarkers":" RUNX1 • HLA-DRB1","pipe":" | ","alterations":" RUNX1 mutation","tags":["RUNX1 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • fludarabine IV • busulfan • uproleselan (APL-106)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/06/2022","start_date":" 10/06/2022","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-05-02"},{"id":"2e3fc686-f418-46cc-8e0c-83866fce21ca","acronym":"NCI-2014-02324","url":"https://clinicaltrials.gov/study/NCT02250937","created_at":"2021-01-18T10:34:04.951Z","updated_at":"2024-07-02T16:35:07.630Z","phase":"Phase 2","brief_title":"Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT02250937 - NCI-2014-02324","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cladribine • fludarabine IV • busulfan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 10/27/2014","start_date":" 10/27/2014","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-04-25"},{"id":"422df941-e330-4ad0-9d42-14c9c566b50a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04872595","created_at":"2021-05-04T11:52:44.720Z","updated_at":"2024-07-02T16:35:08.991Z","phase":"Phase 2","brief_title":"A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant","source_id_and_acronym":"NCT04872595","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53 • HLA-DRB1 • CD34 • CD4","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • HLA-DRB1 • CD34 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 04/30/2021","start_date":" 04/30/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-04-18"},{"id":"7eb97742-0af1-4d32-bf58-4f1cd8878433","acronym":"","url":"https://clinicaltrials.gov/study/NCT04151706","created_at":"2021-01-18T20:15:58.432Z","updated_at":"2024-07-02T16:35:09.442Z","phase":"Phase 2","brief_title":"CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML","source_id_and_acronym":"NCT04151706","lead_sponsor":"Stanford University","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • busulfan • cyclophosphamide intravenous"],"overall_status":"Suspended","enrollment":" Enrollment 20","initiation":"Initiation: 02/27/2020","start_date":" 02/27/2020","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-16"}]